Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Effects of Interferon β-1a and Interferon β-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
The endocannabinoid system and multiple sclerosis.
The "poison chair" treatment for multiple sclerosis.
CCL genes in multiple sclerosis and systemic lupus erythematosus.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Biogen Idec receives notification of PDUFA date extension
Mast cell inflammasome activity in the meninges regulates EAE disease severity.
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Clarity Extension Study
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).
Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
Contribution of different relapse phenotypes to disability in multiple sclerosis.
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.

Pages